The coronavirus disease (Covid-19) vaccine, which is being developed by US pharmaceutical giant Pfizer and German biotechnology company BioNTech, is 90% effective in preventing infections in ongoing phase 3 trials, Pfizer announced on Monday. Monday.
“The first set of results from our Phase 3 Covid-19 vaccine trial provides initial evidence of our vaccine’s ability to prevent Covid-19,” said Pfizer President and CEO Albert Bourla. “We are a significant step closer to giving people around the world a much-needed breakthrough to help end this global health crisis,” added Bourla.
Click here for full Covid-19 coverage
Protection in patients was achieved seven days after the second of two doses and 28 days after the first, according to preliminary findings. The findings are based on an interim analysis performed after 94 participants contracted the disease. The trial will continue until 164 cases have occurred. Preliminary results pave the way for companies to seek an emergency use authorization from regulators if further investigation shows the injection is also safe.
According to supply projections, the companies expect to supply 50 million doses of vaccines worldwide by the end of this year. Up to 1.3 billion doses will be delivered in 2021.
Since its outbreak last year, the coronavirus disease has wreaked havoc around the world, with global cases exceeding 50 million in a grim milestone on Monday. While the death toll exceeds 1,255,000.
.
